OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical and Molecular Hepatology is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease	149
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma	117
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	100
Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017	79
Novel biomarkers for the management of chronic hepatitis B	77
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis	72
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future	67
Recent updates on the management of autoimmune hepatitis	66
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop	65
Application of transient elastography in nonalcoholic fatty liver disease	65
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?	63
<i>Lactobacillus</i> attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis	62
Global incidence and prevalence of nonalcoholic fatty liver disease	62
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach	62
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications	61
Current understanding of primary biliary cholangitis	61
Managing liver cirrhotic complications: Overview of esophageal and gastric varices	56
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region	51
Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH	48
MAFLD: How is it different from NAFLD?	48
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial	48
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	47
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease	46
Autophagy and liver cancer	43
Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging	43

Programmed cell death in alcohol-associated liver disease	42
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease	41
KASL clinical practice guidelines for management of chronic hepatitis B	41
Switching to systemic therapy after locoregional treatment failure: Definition and best timing	40
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name	39
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma	39
Recent advances in nonalcoholic fatty liver disease metabolomics	39
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy	39
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients	39
The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma	38
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective	37
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects	37
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology	37
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease	37